Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$1.17 USD
+0.10 (9.35%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $1.62 +0.45 (38.46%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Tempest Therapeutics, Inc. [TPST]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Path Laid Out With No Surprises; Funding Path Remains to Be Defined; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Focus On Advancing Clinical Programs; Phase 2 Study of TPST-1495 in FAP Expected to Start By YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Freakin'' Stoked as Data Calm the Tempest; Full- Steam Ahead to Phase 3 With Calm Waters Projected
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rapidly Approaching Major Crossroads; TPST-1120 a Leader for 1L HCC SoC Change
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Clinical Pipeline Continues to Advance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Profile Building Preclinical TPST-1120 Data at AACR Further Demonstrate Potential In RCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Clinical Development Ramps Up Across Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TPST-1120 Preclinical Data Bolster Differentiation Across Solid Tumor Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; External Clinical Validation Pushes TPST-1120 Ahead; Registrational Study Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Yup, Huge Move, But Still Below $100M Mkt Cap
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Big Shot Across the Standard of Care Bow; BD a Major Priority; Target Upped to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORPHEUS Framing a Potential Big Win for Tempest; TPST-1120 Focus Piece; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Pipeline Approaches a High Water Mark; Comprehensive TPST-1120 Phase 1b/2 Data in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Presentation Blows Wind Into TPST-1495''s Sails With Promising Look at Phase 1a/1b Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TPST-1495 Data Show Promising Anti-Tumor Activity in Late Stage Cancers; Full Presentation as ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Multiple Upcoming Data Catalysts Set the Tone For a Potentially Transformative Year Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Making Waves; First Look Randomized Phase 1b/2 Favors ''1120 Across the Board
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Updates Highlight Continued Differentiation Across Two Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Data-Rich Year Ahead Across Multiple Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J